Texto: 
Not available.
The Pt will receive combination radiation and chemotherapy.  The overall 5 year survival for Hodgkin's disease with treatment is 82%.  PET scans are a useful means of staging and followup to determine relapse.  This Pt has received a PET scan which will be entered and updated soon.
â€¢ Increased densities in the anterior and posterior mediastinum
â€¢ Enlarged prevascular lymph node, 1.7cm
â€¢ Enlarged Peritracheal lymph node, 1.6cm
â€¢ Moderate pericardial effusion
Classical Hodgkin's Lymphoma, nodular sclerosing type
â€¢ Thymic tumors
â€¢ Pericardial tumors
â€¢ Mediastinal carcinoids
â€¢ Cystic mediastinal lesions
â€¢ Thoracic fungal infections
â€¢ Other causes of lymphadenopathy
21 year old man with a 2 month history of abdominal pain, weight loss, fevers, and chills.
â€¢Lymphomas are divided into Hodgkinâ€™s and non-Hodgkinâ€™s.
â€¢Hodgkinâ€™s lymphoma is characterized by Reed-Sternberg cells, with 4 subtypes.
â€¢In the thorax, nodular sclerosing is the most common subtype with a predilection for the mediastinum.
â€¢Nodular sclerosing accounts for >50% of Hodgkinâ€™s lymphomas.
â€¢Frequency - In the US, 7400 estimated new cases in 2001
â€¢Bimodal distribution - 15-40 years old, >55 years old
â€¢Treatment consists of radiation and/or chemotherapy
â€¢Survival rates, 1yr-93%, 5yr-82%, 10yr-72%, 15yr-63%


Keywords: 
\-\ nodular\\ sclerosing\\ type\\ \\â\\€\\¢\\ thymic\\ tumors\\ \\â\\€\\¢\\ pericardial\\ tumors\\ \\â\\€\\¢\\ mediastinal\\ carcinoids\\ \\â\\€\\¢\\ cystic\\ mediastinal\\ lesions\\ \\â\\€\\¢\\ thoracic\\ fungal\\ infections\\ \\â\\€\\¢\ \(0\)\
\-\ 6cm\\ \\â\\€\\¢\\ moderate\\ pericardial\\ effusion\\ classical\\ hodgkin\ \(0\)\
\-\ posterior\\ mediastinum\\ \\â\\€\\¢\\ enlarged\\ prevascular\\ lymph\\ node\ \(0\)\
\-\ 7cm\\ \\â\\€\\¢\\ enlarged\\ peritracheal\\ lymph\\ node\ \(0\)\
\-\ 55\\ years\\ old\\ \\â\\€\\¢\\ treatment\\ consists\ \(0\)\
\-\ \\â\\€\\¢\\ nodular\\ sclerosing\\ accounts\ \(0\)\
\-\ lymphadenopathy\\ 21\\ year\\ old\\ man\ \(0\)\
\-\ 2001\\ \\â\\€\\¢\\ bimodal\\ distribution\ \(0\)\
\-\ chemotherapy\\ \\â\\€\\¢\\ survival\\ rates\ \(0\)\
\-\ nodular\\ sclerosing\ \(5\)\
\-\ overall\\ 5\\ year\\ survival\ \(1\)\
\-\ 7400\\ estimated\\ new\\ cases\ \(1\)\
\-\ \\â\\€\\¢\\ increased\\ densities\ \(0\)\
\-\ \\â\\€\\¢\\ hodgkin\\ \\â\\€\\™\ \(0\)\
\-\ 40\\ years\\ old\ \(4\)\
\-\ \\â\\€\\¢\\ frequency\ \(0\)\
\-\ \\â\\€\\¢\\ lymphomas\ \(0\)\
\-\ \\â\\€\\¢\ \(8449\)\
\-\ 93\\ \\%\\,\\ 5yr\ \(0\)\
\-\ 72\\ \\%\\,\\ 15yr\ \(0\)\
\-\ 2\\ month\\ history\ \(20\)\
\-\ 82\\ \\%\\,\\ 10yr\ \(0\)\
\-\ receive\\ combination\\ radiation\ \(1\)\
\-\ hodgkin\\ \\â\\€\\™\ \(0\)\
\-\ 82\\ \\%\\.\ \(0\)\
\-\ weight\\ loss\ \(185\)\
\-\ useful\\ means\ \(1\)\
\-\ updated\\ soon\ \(1\)\
\-\ sternberg\\ cells\ \(0\)\
\-\ pet\\ scans\ \(0\)\
\-\ pet\\ scan\ \(0\)\
\-\ mediastinum\ \(228\)\
\-\ determine\\ relapse\ \(1\)\
\-\ common\\ subtype\ \(9\)\
\-\ abdominal\\ pain\ \(486\)\
\-\ 4\\ subtypes\ \(1\)\
\-\ treatment\ \(1387\)\
\-\ hodgkin\ \(1\)\
\-\ chemotherapy\ \(327\)\
\-\ radiation\ \(402\)\
\-\ lymphomas\ \(14\)\
\-\ us\ \(23853\)\
\-\ thorax\ \(504\)\
\-\ staging\ \(52\)\
\-\ reed\ \(14\)\
\-\ received\ \(161\)\
\-\ pt\ \(6402\)\
\-\ predilection\ \(25\)\
\-\ non\ \(1889\)\
\-\ lymphoma\ \(373\)\
\-\ followup\ \(106\)\
\-\ fevers\ \(125\)\
\-\ entered\ \(64\)\
\-\ divided\ \(34\)\
\-\ disease\ \(2755\)\
\-\ chills\ \(104\)\
\-\ characterized\ \(106\)\
\-\ causes\ \(293\)\
\-\ available\ \(430\)\
\-\ anterior\ \(1277\)\
\-\ 63\ \(131\)\
\-\ 50\ \(678\)\
\-\ 1yr\ \(3\)\
\-\ 15\ \(862\)\
\-\ 1\ \(15898\)\
